Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

Aug 05 2017

• By Derrick Gingery

Man crushed by Pill

Related Content

Pay-For-Delay, REMS Reform Legislation Making (Slow) Progress In House

Jul 28 2017

FDA Exploring Whether Public Shaming Can Stop REMS Abuses

Jul 19 2017

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

Jul 04 2017

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

Apr 06 2017

Generic Industry Gets 267 Reasons From FDA To Pursue ANDA Development

Jun 28 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Related Companies

ICU Medical, Inc.

Bausch Health Companies Inc.

Emcure Pharmaceuticals Pvt Ltd.

Arbor Pharmaceuticals, LLC

Additional Topics

United States FDA Generic Drugs Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window